Nothing about the recent past, present, or foreseeable future seems all that compelling.

BioNTech stock crumbled Tuesday after the cofounders of the German biotech announced their plan to step down.

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually ...

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock ...

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. Citing four unnamed people "familiar with the situation," this effort will be based on ...

BioNTech faces a pivotal strategic shift as its founding leadership prepares to depart and recent financial results disappoint the market. The dual announcements on March 10th sent the company's ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase 3 trials, and now Bristol will help to fund further trials. Cash payments ...

The company’s co-founders said they are leaving to start a new mRNA-based company.